Protein Design & Engineering CRO: From Sequence to Candidate
Mosaic designs, engineers, and optimizes therapeutic proteins from early concept through candidate selection, balancing biological activity with manufacturability from day one.
216+
Discovery programs completed to date.
80%
Of scientific staff hold advanced degrees (PhD/MS).
504+
Peer-reviewed publications and patents authored by Mosaic scientists.
50+
Experienced scientists and program leaders.
100%
Research conducted in the USA.
Full-Spectrum Protein Design & Engineering
Mosaic engineers therapeutic proteins across antibodies, cytokines, proteases, soluble receptors, and engineered scaffolds, combining computational design, yeast display, and rigorous analytics to balance biological activity with manufacturability.
Design & Humanization
Computational modeling and humanization strategies that preserve function while improving developability and reducing immunogenicity risk.
Library-Based Protein Engineering (Yeast Display)
Affinity maturation, specificity refinement, and liability reduction through iterative, data-driven yeast display optimization.
Multispecifics & Bispecifics
Modular architectures including common light chain approaches, built for monoclonal-like manufacturability.
Expression & Purification
Platform-agnostic expression across bacterial, yeast, insect, and mammalian systems with custom purification for in vivo use.
Bioconjugation & Glycoengineering
Site-specific modifications and tailored glycosylation to tune PK/PD, targeting, and therapeutic index.
Developability & Optimization
Iterative engineering cycles to improve affinity, stability, solubility, and immunogenicity risk, supported by biophysical characterization.
Modalities we engineer: Antibodies · Cytokines · Proteases · Soluble receptors · Engineered scaffolds
Decision-Ready Deliverables
Every engineering program is designed around your molecule and goals. Typical timelines:
Engineering decisions made early influence manufacturability, stability, and translational performance. Mosaic’s workflows are designed to surface risk early and support confident progression.
Experts From the World’s Top Organizations
Eric Furfine, PhD
Chief Scientific Officer
Led IPO-financed Phase 3 programs at Eleven Biotherapeutics. Built the Adnectin platform (acquired by BMS). Former VP at Regeneron contributing to Eylea development.
Tracy Mullen
Chief Strategy Officer
Former SVP Biopharma at Twist Bioscience (post-Abveris acquisition). Former CEO of Abveris. Antibody discovery leadership experience at Biogen and Adimab platform implementation.
Alexei Kazantsev, PhD
Sr. Director Protein Design and Engineering
Structural and chemical biology expert. Leads protein engineering and PK optimization at Mosaic. Prior research in RNA and protein structural biology using X-ray crystallography and SAXS.
Scott Glaser PhD
SVP, Biologics Discovery
30+ years in biologic drug discovery. Former Director of Antibody Therapeutics at Novartis (GNF) and senior leadership at Pfizer and Biogen. Contributor to 50+ discovery programs and co-inventor on 23 US patents.
Ready to Advance Your Lead Candidate?
Tell us about your molecule and your goals. Our scientific team responds within one business day.
Start a conversation with our scientific team about your discovery program today